Ticketmaster Plans to Have Customers Use Their Cellphones to Verify if They’ve Tested Negative for COVID-19!
Ticketmaster Plans to Have Customers Use Their Cellphones to Verify if They’ve Tested Negative for COVID-19!
Get ready for the new norm. In a recent announcement Ticketmaster stated they the plan on checking the coronavirus vaccination status of event-goers prior to shows once a treatment is approved and rolled out.
That’s right if you plan on attending an event after a vaccine is approved and go through Ticketmaster you’ll have to verify that you’ve tested negative for the virus within the last 24-72 hours.
According to the plan, guests “will utilize three separate components, including the California-based company’s digital ticketing app, third-party health information firms like CLEAR Health Pass and testing/vaccination distributors like Labcorp or CVS Minute Clinic.”
Ticketmaster has stated that they will not store the medical data or look to access any records. For those that have tested negative and would like to attend an event you’ll have to instruct a lab to send over your test results to the companies listed above (CLEAR Health Pass or IBM’s Digital Health Pass) and they in-turn would verify the ticket-holder’s status to Ticketmaster. Anyone who tests positive will not be permitted to attend.
Since all attendees are required to be tested the reselling of tickets will not be permitted. Ticketmaster president Mark Yovich told Billboard he expects demand for digital screening services to skyrocket once a vaccination is ultimately approved and distributed.
“We’re already seeing many third-party health care providers prepare to handle the vetting — whether that is getting a vaccine, taking a test or other methods of review and approval — which could then be linked via a digital ticket so everyone entering the event is verified,” Yovich said.
According to the NY Post “Pfizer and German biotech firm BioNTech announced that they expect to produce up to 50 million doses of its vaccine candidate — BNT162b2 — for global distribution by the end of 2020 and as many as 1.3 billion doses next year.”
